CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
Cluster of differentiation 47 (CD47) is a transmembrane protein highly expressed in tumor cells that interacts with signal regulatory protein alpha (SIRPα) and triggers a “don’t eat me” signal to the macrophage, inhibiting phagocytosis and enabling tumor escape from immunosurveillance. The CD47-SIRP...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2310248 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576533199323136 |
|---|---|
| author | Dan Zhu Haralambos Hadjivassiliou Catherine Jennings David Mikolon Massimo Ammirante Sharmistha Acharya Jon Lloyd Mahan Abbasian Rama Krishna Narla Joseph R. Piccotti Katie Stamp Ho Cho Kandasamy Hariharan |
| author_facet | Dan Zhu Haralambos Hadjivassiliou Catherine Jennings David Mikolon Massimo Ammirante Sharmistha Acharya Jon Lloyd Mahan Abbasian Rama Krishna Narla Joseph R. Piccotti Katie Stamp Ho Cho Kandasamy Hariharan |
| author_sort | Dan Zhu |
| collection | DOAJ |
| description | Cluster of differentiation 47 (CD47) is a transmembrane protein highly expressed in tumor cells that interacts with signal regulatory protein alpha (SIRPα) and triggers a “don’t eat me” signal to the macrophage, inhibiting phagocytosis and enabling tumor escape from immunosurveillance. The CD47-SIRPα axis has become an important target for cancer immunotherapy. To date, the advancement of CD47-targeted modalities is hindered by the ubiquitous expression of the target, often leading to rapid drug elimination and hematologic toxicity including anemia. To overcome those challenges a bispecific approach was taken. CC-96673, a humanized IgG1 bispecific antibody co-targeting CD47 and CD20, is designed to bind CD20 with high affinity and CD47 with optimally lowered affinity. As a result of the detuned CD47 affinity, CC-96673 selectively binds to CD20-expressing cells, blocking the interaction of CD47 with SIRPα. This increased selectivity of CC-96673 over monospecific anti-CD47 approaches allows for the use of wild-type IgG1 Fc, which engages activating crystallizable fragment gamma receptors (FcγRs) to fully potentiate macrophages to engulf and destroy CD20+ cells, while sparing CD47+CD20− normal cells. The combined targeting of anti-CD20 and anti-CD47 results in enhanced anti- tumor activity compared to anti-CD20 targeting antibodies alone. Furthermore, preclinical studies have demonstrated that CC-96673 exhibits acceptable pharmacokinetic properties with a favorable toxicity profile in non-human primates. Collectively, these findings define CC-96673 as a promising CD47 × CD20 bispecific antibody that selectively destroys CD20+ cancer cells via enhanced phagocytosis and other effector functions. |
| format | Article |
| id | doaj-art-2baf8cb3663d44fba094537b05a4fc5d |
| institution | Kabale University |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-2baf8cb3663d44fba094537b05a4fc5d2025-01-31T04:19:38ZengTaylor & Francis GroupmAbs1942-08621942-08702024-12-0116110.1080/19420862.2024.2310248CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphomaDan Zhu0Haralambos Hadjivassiliou1Catherine Jennings2David Mikolon3Massimo Ammirante4Sharmistha Acharya5Jon Lloyd6Mahan Abbasian7Rama Krishna Narla8Joseph R. Piccotti9Katie Stamp10Ho Cho11Kandasamy Hariharan12Department of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USADepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USADepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USADepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USAOncogenesis Thematic Research Center, Bristol Myers Squibb, San Diego, CA, USADepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USADepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USADepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USAOncogenesis Thematic Research Center, Bristol Myers Squibb, San Diego, CA, USADepartment of Nonclinical Development, Bristol Myers Squibb, San Diego, CA, USADepartment of Nonclinical Development, Bristol Myers Squibb, San Diego, CA, USADepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USADepartment of Discovery Biotherapeutics, Bristol Myers Squibb, San Diego, CA, USACluster of differentiation 47 (CD47) is a transmembrane protein highly expressed in tumor cells that interacts with signal regulatory protein alpha (SIRPα) and triggers a “don’t eat me” signal to the macrophage, inhibiting phagocytosis and enabling tumor escape from immunosurveillance. The CD47-SIRPα axis has become an important target for cancer immunotherapy. To date, the advancement of CD47-targeted modalities is hindered by the ubiquitous expression of the target, often leading to rapid drug elimination and hematologic toxicity including anemia. To overcome those challenges a bispecific approach was taken. CC-96673, a humanized IgG1 bispecific antibody co-targeting CD47 and CD20, is designed to bind CD20 with high affinity and CD47 with optimally lowered affinity. As a result of the detuned CD47 affinity, CC-96673 selectively binds to CD20-expressing cells, blocking the interaction of CD47 with SIRPα. This increased selectivity of CC-96673 over monospecific anti-CD47 approaches allows for the use of wild-type IgG1 Fc, which engages activating crystallizable fragment gamma receptors (FcγRs) to fully potentiate macrophages to engulf and destroy CD20+ cells, while sparing CD47+CD20− normal cells. The combined targeting of anti-CD20 and anti-CD47 results in enhanced anti- tumor activity compared to anti-CD20 targeting antibodies alone. Furthermore, preclinical studies have demonstrated that CC-96673 exhibits acceptable pharmacokinetic properties with a favorable toxicity profile in non-human primates. Collectively, these findings define CC-96673 as a promising CD47 × CD20 bispecific antibody that selectively destroys CD20+ cancer cells via enhanced phagocytosis and other effector functions.https://www.tandfonline.com/doi/10.1080/19420862.2024.2310248CD20CD47detunenon-Hodgkin’s lymphomaphagocytosis |
| spellingShingle | Dan Zhu Haralambos Hadjivassiliou Catherine Jennings David Mikolon Massimo Ammirante Sharmistha Acharya Jon Lloyd Mahan Abbasian Rama Krishna Narla Joseph R. Piccotti Katie Stamp Ho Cho Kandasamy Hariharan CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma mAbs CD20 CD47 detune non-Hodgkin’s lymphoma phagocytosis |
| title | CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma |
| title_full | CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma |
| title_fullStr | CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma |
| title_full_unstemmed | CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma |
| title_short | CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma |
| title_sort | cc 96673 bms 986358 an affinity tuned anti cd47 and cd20 bispecific antibody with fully functional fc selectively targets and depletes non hodgkin s lymphoma |
| topic | CD20 CD47 detune non-Hodgkin’s lymphoma phagocytosis |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2024.2310248 |
| work_keys_str_mv | AT danzhu cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT haralamboshadjivassiliou cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT catherinejennings cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT davidmikolon cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT massimoammirante cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT sharmisthaacharya cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT jonlloyd cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT mahanabbasian cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT ramakrishnanarla cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT josephrpiccotti cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT katiestamp cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT hocho cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma AT kandasamyhariharan cc96673bms986358anaffinitytunedanticd47andcd20bispecificantibodywithfullyfunctionalfcselectivelytargetsanddepletesnonhodgkinslymphoma |